早期非小细胞肺癌患者吸烟行为:ECOG-ACRIN 1505试验报告
该研究基于ECOG-ACRIN 1505三期试验,对1501例IB-IIIA期NSCLC术后患者进行吸烟行为问卷随访。90%患者有吸烟史,入组后吸烟量显著减少或戒烟;从未吸烟者较当前或既往吸烟者3-5级毒性更低且总生存更优,但无病生存无显著差异。
要点
- 早期NSCLC术后患者中90%有吸烟史,入组后94%报告每日吸烟量为零或减少。
- 从未吸烟者较当前吸烟者3-5级毒性发生率更低(68% vs 72%,p=0.05)。
- 从未吸烟者较当前和既往吸烟者总生存更优(校正HR 0.54,p=0.005;HR 0.68,p=0.03)。
核心结论
- 早期NSCLC患者入组试验后吸烟减少和戒烟率高,从未吸烟者毒性更少且总生存更优,但无病生存无显著差异。
研究设计与样本
- ECOG-ACRIN 1505是一项辅助治疗三期试验的二次分析,共纳入1501例IB-IIIA期NSCLC术后患者。
- 患者在基线及3、6、9、12个月完成吸烟习惯问卷,应答率分别为99.8%、95%、94%、93%、93%。
主要发现
- 90%患者报告当前或既往吸烟史;入组时非吸烟者中60%报告诊断后(随机化前)吸烟,但12个月时仅1%报告吸烟。
- 12个月时94%应答者报告每日吸烟为零或减少。
- 3-5级毒性发生率在从未、既往和当前吸烟者中分别为68%、76%和72%(p=0.05)。
- 从未吸烟者相对于当前吸烟者的无病生存HR为0.93(p=0.64),相对于既往吸烟者为HR 1.05(p=0.72)。
- 从未吸烟者相对于当前吸烟者的总生存校正HR为0.54(p=0.005),相对于既往吸烟者为校正HR 0.68(p=0.03)。
临床怎么用
- 在早期NSCLC术后患者中应重视吸烟行为评估与戒烟干预,因入组后吸烟减少和戒烟率较高。
- 从未吸烟者治疗毒性更低且总生存更优,提示吸烟状态可能影响治疗耐受与生存。
局限性
- 吸烟行为与生存的关联为次要终点分析,非随机比较,可能存在混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Smoking cessation has been reported to benefit patients even after a diagnosis of lung cancer. We studied the smoking behavior of patients who participated in a phase 3 trial of adjuvant therapy following resection of stages IB-IIIA NSCLC. METHODS: The ECOG-ACRIN 1505 was conducted to determine whether the addition of bevacizumab to adjuvant chemotherapy would improve overall survival (OS) for patients with early-stage NSCLC. Studying the association between smoking status and OS was a secondary end point. Patients completed a questionnaire on their smoking habits at baseline, 3, 6, 9, and 12 months. RESULTS: A total of 1501 patients were enrolled, and 99.8%, 95%, 94%, 93%, and 93% responded to the questionnaire at baseline, 3, 6, 9, and 12 months, respectively. A total of 90% reported a current or previous history of cigarette smoking. In addition, 60% of nonsmokers at enrollment reported smoking after diagnosis (before randomization); however, 1% of them reported smoking at 12 months. Furthermore, 94% of the respondents smoked none/fewer cigarettes daily at 12 months. The incidence of grades 3-5 toxicity on treatment was 68%, 76%, and 72% in never, former, and current smokers, respectively (p = 0.05). The disease-free survival for never-smokers relative to current and former smokers was (hazard ratio [HR] 0.93, p = 0.64 and HR 1.05, p = 0.72), and OS was (adjusted HR for death 0.54, p = 0.005 and adjusted HR for death 0.68, p = 0.03), respectively. CONCLUSIONS: This is the first comprehensive, prospective report of smoking habits in patients with NSCLC patients from a phase III early-stage trial. There was a high rate of smoking reduction and cessation following study entry. The disease-free survival did not differ significantly between smokers and never smokers, though there were less grade 3-5 toxicities and more favorable OS in never-smokers.
引用
- Steuer CE, Jegede OA, Dahlberg SE, et al. Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial. J Thorac Oncol. 2021. PMID: 33539971. doi:10.1016/j.jtho.2020.12.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。